Latest news with #HealthCareSystem
Yahoo
25-05-2025
- Health
- Yahoo
Group awaiting approval of Summa purchase shares extensive vision for using AI
The venture capital firm bankrolling Health Assurance Transformation Company's purchase — pending regulatory approval — of Summa Health has been lobbying U.S. government officials for new health care policies espousing greater use of artificial intelligence in medical settings. HATCo owner General Catalyst has published a range of materials advocating for policies encouraging health care providers to use AI while delivering care and equip patients with AI to monitor vital signs in their daily lives. In 2024, General Catalyst launched an initiative called the General Catalyst Institute. The institute published a March report that said AI could be implemented throughout the entire health care system — with the federal government getting rid of regulations that General Catalyst and its allies see as burdensome. The integration of AI into health care is among the chief concerns opponents of the Summa deal have expressed about the potential HATCo ownership, with fears that it will result in less attentive care and the elimination of jobs. One of the proposals in the GCI paper — which General Catalyst spokesperson Molly Gillis said via email was "drafted in collaboration with over two dozen healthcare experts and entrepreneurs" — is for the U.S. Food and Drug Administration to "create an expedited pathway for reviewing and approving AI-driven healthcare solutions." The paper also shares the firm's vision of the U.S. Department of Health and Human Services broadly supporting the "Make America Healthy Again" movement championed by President Donald Trump and Robert F. Kennedy Jr. For example, the paper said the department can create "regional healthcare innovation sandboxes" that would test "interventions that address root causes of chronic disease, including environmental factors and food additives, while maintaining rigorous scientific standards." Gillis, partner and chief of staff at General Catalyst, said the General Catalyst Institute is nonpartisan. She did not directly answer a Beacon Journal reporter's question about whether General Catalyst is concerned about Kennedy, the HHS secretary — opposing vaccines, questioning antidepressants and advocating for the removal of fluoride from public water. The effectiveness of multiple vaccines and antidepressants has been thoroughly tested and is widely agreed upon in the medical community, while new drugs go through multi-tiered government approval processes. Fluoride is added to water to prevent cavities, according to the U.S. Centers for Disease Control and Prevention. "Our engagement in Washington reflects our belief that healthcare transformation requires input from leaders across the public and private sectors, regardless of who is in office," Gillis said. More broadly, Gillis said, "General Catalyst's commitment to fulfilling and accelerating the promise of Health Assurance, which prioritizes and incentivizes keeping people well, remains steadfast. We strongly believe that accelerating innovation and advancing value-based care through patient-centered solutions will create better health outcomes for all Americans." Summa spokesman Mike Bernstein said via email that Summa is fully aligned with General Catalyst and HATCo's vision of creating a new health care model "that transforms the current sick care system into a resilient, proactive system designed to help people stay well, reduce cost through innovation and make quality care more affordable and accessible for everyone. We view this work as non-partisan and we seek feedback from people throughout the public and private sectors, regardless of who is in office or what political affiliations they hold." Summa leaders could not directly address the GCI report, Bernstein said. General Catalyst Institute also praised decisions surrounding AI by the Trump administration in a March 14 letter to the National Coordination Office at the U.S. government's Networking and Information Technology Research and Development Program. "President Trump has demonstrated his commitment — and that of his administration — to strengthening American leadership in the global AI race in a variety of ways, including prioritizing the appointment of the first ever White House AI Czar in David Sacks, and nominating and appointing many qualified individuals to shape and implement his administration's policies across this important topic," the letter said. While the March 14 letter was not fully focused on health care as the GCI report was, it cited health care as an area where AI could be applied, stating that AI can "analyze medical data, help with diagnostic tools, predict disease outbreaks, and personalize treatment plans." Matthew Charlebois, who is opposed to the proposed Summa-HATCo deal and a member of the Summa Is Not For Sale coalition, said it was "not surprising at all" to him that General Catalyst would try to curry favor with the Trump administration. "If Kamala Harris won the election, they would do something similar with her administration in terms of trying to win their support," Charlebois said. But as far as General Catalyst's proposals themselves, he said, "It very much sounds like Akron and Summa in particular is being used as an experimental guinea pig subject to test out these largely unproven scientific experiments with regards to implementing AI technology into health care." Charlebois said General Catalyst wants "less regulations on the health care industry so they can extract more profits from patients and they can work their workers even harder." The General Catalyst Institute wrote in the March 14 letter, "The adoption of intelligent AI agents allows humans to focus on work that requires creativity, emotional intelligence, and complex decision-making. As this trend continues, managing AI agents will likely become a new function, or part of an expanded role." Summa's Bernstein said, "Importantly, technology will be used to support and empower our workforce, not replace it, so that clinicians and staff can focus fully on what matters most: delivering compassionate, high-quality care. "As part of this transformation, we remain committed to investing in our people through workforce development, clinical training and enhanced engagement, recognizing that they are vital to our long-term success." Hemant Taneja, General Catalyst's CEO, and Dr. Stephen Klasko, an adviser to the firm and former president and CEO of Thomas Jefferson University and Jefferson Health, in 2020 wrote a book called "UnHealthcare." In it, they proposed that a new "health assurance" system could replace the "sick care" system. "Building health assurance is one of the greatest business opportunities in history," they wrote. "How often in any generation does a multi-trillion-dollar global industry go through a reinvention?" Many of the proposals listed in the book focus on using technology to detect symptoms so physical health assurance locations don't get crowded, consumers can make more choices about their health to improve their wellbeing and hospitals can lower costs. "Failure to take medications is one of the chief reasons patients end up back at a doctor's office or emergency room," the authors wrote. "Soon, pills will contain a tiny ingestible chip that can tell an app whether you're following through." Later in the book, Taneja and Klasko wrote, "AI-driven chat bots will 'talk' to mental health patients — we already know that many younger people are more likely to be honest with a chat bot than a psychologist. AI will help keep an eye on seniors 24/7, enabling them to live at home longer." In its March report, the General Catalyst Institute addressed concerns about privacy, safety and security as it proposed the rollout of AI throughout the health care system. Ensuring privacy, for instance, would be done in part through data encryption and anonymization, the paper said. A document signed by Summa and HATCo leaders said HATCo and its affiliates will encourage portfolio companies to "locate their headquarters in the Summa Community." The Beacon Journal obtained the report from the Ohio Attorney General's Office, which is reviewing the proposed sale. Charlebois said he doesn't see how patients, workers and the community would benefit from General Catalyst's AI push. "None of these are proposals that are about meeting the needs of Akronites," Charlebois said. "All these are proposals about, 'How can we profit our portfolio companies and ourselves and take over the health care industry and run it like a for-profit corporation?'" Meanwhile, Summa is already using AI for multiple services, Bernstein said, citing "sepsis detection, transcription, radiology interpretation and lung cancer screening." The hospital system uses a "comprehensive vetting process" before implementing new technologies, Bernstein said, adding that these are technologies from various companies, including some in General Catalyst's investment portfolio. He declined to name specific General Catalyst portfolio companies that provide the technologies, citing that "we are still in the early stages of this work and still in regulatory review" with the acquisition deal. Other Northeast Ohio hospital systems are using similar technologies, too. University Hospitals radiologists interpret results with AI, and Cleveland Clinic uses AI to transcribe provider-patient interactions. Providers from both hospital systems have talked positively of the technologies. Charlebois said Summa employees in inpatient and outpatient patient care settings have joined the Summa Is Not For Sale coalition. He declined, however, to share how many Summa employees have joined the group — saying they all want to remain anonymous. Gillis said General Catalyst's work over the past several years has had a priority of "making healthcare more accessible and affordable for all Americans." "As we work towards finalizing our transaction with Summa Health, which includes maintaining its charity care policy, community benefit, and essential services, our vision is to reimagine and evolve healthcare to work better for patients, providers, and communities in the Greater Akron region and across America — through partnership, innovation, and an unwavering focus on health outcomes for all people," Gillis said. Patrick Williams covers growth and development for the Akron Beacon Journal. He can be reached by email at pwilliams@ or on X, formerly known as Twitter, @pwilliamsOH. Sign up for the Beacon Journal's business and consumer newsletter, "What's the deal?," at This article originally appeared on Akron Beacon Journal: HATCo owner General Catalyst would bring heavy AI focus to Summa
Medscape
13-05-2025
- Health
- Medscape
Preoperative SGLT2 Use Linked to Lower AKI Risk Post-Surgery
Preoperative use of sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced the risk for acute kidney injury (AKI) by 31% after surgery, according to this retrospective, case-control study. METHODOLOGY: Case reports and small retrospective studies have suggested an increased risk for postoperative euglycemic ketoacidosis and AKI in patients using SGLT2 inhibitors preoperatively; however, the actual risks for these conditions are not well understood. Researchers conducted a retrospective case-control study using data from the Veterans Affairs Health Care System National Registry (2014-2022) to evaluate risks for postoperative euglycemic ketoacidosis, AKI, and mortality within 30 days after surgery in 7439 preoperative SGLT2 inhibitor users (mean age, 67.7 years; 96.7% men) and 33,489 propensity-matched nonusers (mean age, 67.9 years; 96.4% men). Long-term use of preoperative SGLT2 inhibitors was defined as having three or more fills of outpatient prescription within 3 months prior to surgery or less than a 180-day gap since the most recent fill according to pharmacy registries. The duration of SGLT2 inhibitor suspension prior to the surgical procedures was not available for this cohort. The primary outcome was postoperative euglycemic ketoacidosis; secondary outcomes were postoperative AKI and 30-day in-hospital mortality. TAKEAWAY: Preoperative SGLT2 inhibitor users had reduced risks for AKI (odds ratio [OR], 0.69; 95% CI, 0.62-0.78) and 30-day mortality (OR, 0.70; 95% CI, 0.55-0.88) after surgery but had a modestly increased risk for postoperative euglycemic ketoacidosis (OR, 1.11; 95% CI, 1.05-1.17). The renal protective effects of SGLT2 inhibitors were not seen in patients who underwent cardiac surgery or emergency procedures but were observed in those who underwent noncardiac surgery (OR, 0.63; 95% CI, 0.56-0.71) and nonemergency procedures (OR, 0.64; 95% CI, 0.56-0.72). The increased risk for postoperative euglycemic ketoacidosis among SGLT2 inhibitor users was most prominent in those who underwent cardiac surgery (OR, 1.30; 95% CI, 1.11-1.54), whereas the greatest mortality benefits were observed in patients who underwent emergency surgery (OR, 0.49; 95% CI, 0.26-0.93). IN PRACTICE: 'Renoprotective effects of SGLT2i [SGLT2 inhibitor] in the perioperative setting could have far-reaching implications given the annual volume of patients undergoing surgical procedures and the burden of postoperative AKI,' the authors concluded. SOURCE: This study was led by Roberta Teixeira Tallarico, MD, Department of Anesthesia and Perioperative Care, University of California San Francisco. It was published online in JAMA Surgery . LIMITATIONS: The observational nature of this study limited the ability to establish direct causality. The exact timing of the last SGLT2 inhibitor administration before surgery was unknown, and the absence of ketone measurements limited their diagnostic criteria for euglycemic ketoacidosis. The study population primarily consisted of White male veterans older than 60 years, which limited the generalizability of the results. DISCLOSURES: This study was supported by the National Institute of General Medical Sciences of the National Institutes of Health, the statistical core of the University of California San Francisco ( UCSF) Pepper Center through the National Institutes of Health, the UCSF FAST-CaR Seed Research Grant, and UCSF Anesthesia Research. Some authors reported receiving grants and personal fees from and having other ties with certain institutions and pharmaceutical companies including the funding sources.
